StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
New Gilead Sciences (GILD) HIV Concerns 'Overdone' - RBC
October 31, 2018 12:24 PM
RBC Capital analyst Brian Abrahams weighed in on Gilead Sciences (NASDAQ: GILD) amid new debates about the long-term longevity of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Gilead Sciences (GILD) Falls to Low, Down 5.6%
October 31, 2018 11:35 AM
Gilead Sciences (GILD), Tango Therapeutics Announce Pact to Develop Next-Generation Targeted Immuno-Oncology Therapies
October 31, 2018 8:31 AM
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
October 31, 2018 8:30 AM
Gilead Sciences (GILD) Reports 96-Wk Data from Phase 3 Study of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for HIV-1 Treatment in Adults New to HIV Therapy
October 30, 2018 7:17 AM
